Miraz Rahman

May 28, 2024 | kcl.ac.uk | David Thurston |Miraz Rahman

The investment raised at the close of its Series B funding round will enable Pheon Therapeutics (Pheon) to take three new Antibody-Drug Conjugates (ADCs), used to treat cancer, through clinical trials. Pheon Therapeutics, a biotech spinout with its origins in research carried out at the Institute of Pharmaceutical Sciences (IPS) at King’s, has raised $120 million in Series B funding to further develop its pre-clinical and clinical pipeline.